newsfilter
← Latest News
GlobeNewswire·

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

  • Nurix Therapeutics initiated the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL).
  • Phase 1 data presented at ASH 2025 showed an 83% objective response rate & 22.1-month median progression-free survival for bexobrutideg in heavily pretreated CLL patients.
  • The 600 mg once-daily dose was selected for the pivotal Phase 2 study based on superior response rates & favorable trends compared to the 200 mg dose.
  • Bexobrutideg also demonstrated a 75% objective response rate in patients with relapsed/refractory Waldenström macroglobulinemia.
  • Preclinical data for the IRAK4 degrader GS-6791 in collaboration with Gilead showed robust inhibition of IL-1 & IL-36 signaling.
  • The company raised $250 million through an underwritten stock offering in October 2025 to strengthen its balance sheet.
  • Cash, cash equivalents, & marketable securities totaled $592.9 million as of November 30, 2025.
  • Fiscal fourth quarter revenue was $13.6 million, while full-year 2025 revenue reached $84.0 million due to $30 million in license revenue.
  • Research & development expenses increased to $316.9 million for the twelve months ended November 30, 2025.
  • Net loss for the twelve months ended November 30, 2025, was $264.5 million, or $3.05 per share.
  • Roger Dansey, M.D., was appointed to the Board of Directors in November 2025 to support late-stage development.
  • A global Phase 3 trial for bexobrutideg is planned for initiation in the first half of 2026.
  • Clinical enrollment continues for NX-1607, a CBL-B inhibitor, showing dose-dependent target engagement & immune activation.
  • Nurix expects to provide further preclinical & clinical updates in 2026 to major medical conferences.